VERU INC. SEC 10-Q Report

VERU INC., a biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases, has released its Form 10-Q report for the second quarter of 2025. The report provides a comprehensive overview of the company's financial performance and key business developments during the period.

Financial Highlights

• Net Revenues: $0 million. The company had no net revenues during the three months ended June 30, 2025, as the FC2 business was sold on December 30, 2024.
• Gross Profit: Gross profit from discontinued operations was $0 for the three months ended June 30, 2025, due to the sale of the FC2 business.
• Operating Loss from Continuing Operations: $(7.5) million, reflecting a decrease in operating expenses compared to the prior year.
• Net Loss from Continuing Operations: $(7.3) million, improved from a net loss of $(10.3) million in the prior year period.
• Net Loss: $(7.3) million, improved from a net loss of $(11.0) million in the prior year period.
• Net Loss Per Basic and Diluted Common Shares Outstanding: $(0.50), improved from $(0.75) in the prior year period.

Business Highlights

• Obesity Program: The company is developing enobosarm, an oral selective androgen receptor modulator (SARM), to address muscle loss in sarcopenic obese or overweight older patients receiving GLP-1 receptor agonists. The Phase 2b QUALITY clinical trial has shown promising results in preserving lean body mass and enhancing fat loss.
• Phase 2b QUALITY Clinical Trial: This trial is the first to demonstrate the effects of a muscle preservation drug on body composition in older patients using GLP-1 receptor agonists. The trial met its primary endpoint with significant preservation of lean body mass and improved body composition.
• Future Outlook for Enobosarm: Following the successful Phase 2b trial, the company plans to advance enobosarm into a Phase 3 obesity clinical trial to further evaluate its efficacy in preserving muscle mass and enhancing fat loss in combination with semaglutide.
• Sabizabulin Development: Sabizabulin, an oral microtubule disruptor, is being developed as a broad anti-inflammatory agent to address atherosclerotic cardiovascular disease, highlighting the company's focus on cardiometabolic and inflammatory diseases.
• FC2 Business Sale: The company completed the sale of its FC2 Female Condom business, marking a strategic shift to focus on its biopharmaceutical pipeline, particularly in cardiometabolic and inflammatory disease treatments.

SEC Filing: VERU INC. [ VERU ] - 10-Q - Aug. 12, 2025